| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 28.60M | 28.60M | 27.60M | 22.77M | 16.55M | 8.39M |
| Gross Profit | 4.91M | 28.60M | 4.89M | 2.14M | -202.00K | 2.77M |
| EBITDA | -4.68M | -808.00K | -331.00K | -1.26M | -2.28M | 1.02M |
| Net Income | -6.16M | -6.16M | -5.11M | -6.91M | -4.45M | -383.62K |
Balance Sheet | ||||||
| Total Assets | 54.29M | 54.29M | 59.65M | 62.53M | 63.91M | 47.05M |
| Cash, Cash Equivalents and Short-Term Investments | 4.78M | 4.78M | 5.04M | 8.81M | 6.35M | 14.12M |
| Total Debt | 3.26M | 3.26M | 1.66M | 755.00K | 1.12M | 799.36K |
| Total Liabilities | 12.36M | 12.36M | 12.52M | 15.31M | 15.33M | 4.96M |
| Stockholders Equity | 41.93M | 41.93M | 47.14M | 47.22M | 48.58M | 42.09M |
Cash Flow | ||||||
| Free Cash Flow | 440.00K | -1.84M | -4.51M | -1.88M | -4.83M | -2.64M |
| Operating Cash Flow | 609.00K | 609.00K | -492.00K | 768.00K | -2.32M | 240.65K |
| Investing Cash Flow | -2.45M | -2.45M | -4.02M | -2.65M | -5.16M | -2.98M |
| Financing Cash Flow | 1.58M | 1.58M | 749.00K | 4.34M | -286.00K | 12.65M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | AU$167.87M | 104.17 | 1.89% | ― | 10.06% | ― | |
52 Neutral | AU$19.47M | -10.79 | -17.05% | ― | 28.91% | -1050.00% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$53.76M | -8.92 | -13.83% | ― | 3.61% | -17.03% | |
48 Neutral | AU$96.34M | -16.86 | -12.35% | ― | 15.99% | 22.05% | |
42 Neutral | AU$56.43M | -6.06 | -8647.54% | ― | 25.98% | 22.10% |
Beamtree Holdings Limited has announced that it will release its half-year results for the first half of FY26 on 25 February 2026 and will host an investor webinar the same day at 9:00am AEST to discuss the performance. The scheduled update underscores the company’s ongoing communication with investors as it pursues growth in AI-enabled healthcare analytics and decision support, with stakeholders likely to focus on how its diversified product segments are translating into operational and financial progress in a competitive digital health landscape.
The most recent analyst rating on (AU:BMT) stock is a Hold with a A$0.19 price target. To see the full list of analyst forecasts on Beamtree Holdings Ltd stock, see the AU:BMT Stock Forecast page.
Beamtree Holdings Limited has applied for quotation on the ASX of 46,045 new fully paid ordinary shares issued on 13 January 2026 under its Employee Incentive Plan, pursuant to salary contribution arrangements. The modest equity issuance reflects the company’s ongoing use of share-based remuneration to align staff interests with shareholders, signalling continued emphasis on talent retention and engagement without materially altering the company’s capital structure.
The most recent analyst rating on (AU:BMT) stock is a Hold with a A$0.22 price target. To see the full list of analyst forecasts on Beamtree Holdings Ltd stock, see the AU:BMT Stock Forecast page.
Beamtree Holdings Limited has issued 1,000,000 unquoted performance rights under its employee incentive scheme, with the new securities designated under ASX code BMTAC and issued on 9 January 2026. The performance rights are subject to transfer restrictions and will not be quoted on the ASX until those restrictions lapse, indicating the company’s ongoing use of equity-based remuneration to retain and motivate staff while limiting immediate market dilution.
The most recent analyst rating on (AU:BMT) stock is a Hold with a A$0.22 price target. To see the full list of analyst forecasts on Beamtree Holdings Ltd stock, see the AU:BMT Stock Forecast page.
Beamtree Holdings Limited has notified the market of the issue of 700,000 unquoted performance rights under its employee incentive scheme, with an issue date of 14 November 2025. The new equity allocation forms part of Beamtree’s strategy to align staff and executive remuneration with long-term shareholder value, using equity-based incentives that are subject to trading restrictions and are not quoted on the ASX, thereby reinforcing retention and performance objectives without immediately diluting the quoted share base.
The most recent analyst rating on (AU:BMT) stock is a Hold with a A$0.22 price target. To see the full list of analyst forecasts on Beamtree Holdings Ltd stock, see the AU:BMT Stock Forecast page.
Beamtree Holdings Limited has announced the approval of its amended Constitution following a special resolution by shareholders at the recent Annual General Meeting. This development signifies a strategic move that may impact the company’s governance structure and operational framework, potentially influencing its market positioning and stakeholder relations.
The most recent analyst rating on (AU:BMT) stock is a Hold with a A$0.22 price target. To see the full list of analyst forecasts on Beamtree Holdings Ltd stock, see the AU:BMT Stock Forecast page.
Beamtree Holdings Limited announced that all resolutions were passed by shareholders at their Annual General Meeting. This outcome reflects strong shareholder support and may positively influence the company’s strategic direction and governance, reinforcing its industry position and stakeholder confidence.
The most recent analyst rating on (AU:BMT) stock is a Hold with a A$0.19 price target. To see the full list of analyst forecasts on Beamtree Holdings Ltd stock, see the AU:BMT Stock Forecast page.
Beamtree Holdings Limited held its 2025 Annual General Meeting, highlighting significant innovations and strategic leadership appointments. The company announced the successful launch of its data analytics platform in Australia, with plans to expand into the UK market in early 2026 in partnership with the UK NHS Confederation. Additionally, Beamtree’s Picq Audit product has achieved strong market fit and is expanding from the public to the private sector and internationally, with revenue exceeding expectations.
The most recent analyst rating on (AU:BMT) stock is a Hold with a A$0.19 price target. To see the full list of analyst forecasts on Beamtree Holdings Ltd stock, see the AU:BMT Stock Forecast page.
Beamtree Holdings Limited has announced the appointment of Michelle Spiller as Chief Financial Officer and James Price as General Manager Sales for Australia and New Zealand. Michelle brings a wealth of experience in financial management and strategic planning from her previous roles in ASX-listed technology companies, while James has a strong background in health, aged care, and technology sectors. These appointments are expected to strengthen Beamtree’s executive team, enhance its operational and strategic priorities, and bolster its focus on core solutions and customer service in key markets.
The most recent analyst rating on (AU:BMT) stock is a Hold with a A$0.19 price target. To see the full list of analyst forecasts on Beamtree Holdings Ltd stock, see the AU:BMT Stock Forecast page.